Method for producing long-acting hormone receptor antagonists
Optimizing culture conditions for recombinant growth hormone receptor antagonists by varying temperature and glucose levels enhances productivity and reduces host cell proteins, addressing existing challenges in producing high-quality, pure therapeutic proteins.
Patent Information
- Application Number
- PCT/KR2023/012247
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-01
- Filing Date
- 2023-08-18
- Publication Date
- 2024-12-05
AI Technical Summary
Current methods for producing recombinant long-acting growth hormone receptor antagonists face challenges in increasing productivity and reducing host cell protein expression, which affects the quality and purity of the final product, necessitating improved cell culture conditions and purification processes.
The method involves optimizing culture conditions such as temperature, initial cell concentration, and glucose concentration in the medium, specifically by culturing host cells at varying temperatures and glucose levels to enhance productivity and reduce host cell protein expression, using techniques like fed-batch and perfusion cultures to maintain optimal residual glucose concentrations and suppress host cell protein production.
This approach significantly increases the productivity and quality of recombinant long-acting growth hormone receptor antagonists, achieving higher expression levels and lower host cell protein content, thereby improving the purity and safety of the therapeutic protein, aligning with regulatory standards and facilitating more efficient production processes.
Smart Images

Figure KR2023012247_05122024_PF_FP_ABST
Abstract
Description
Method for producing a long-acting hormone receptor antagonist
[0001] The present invention relates to a method for producing a recombinant long-acting hormone receptor antagonist, particularly a native long-acting hormone receptor antagonist or a mature long-acting hormone receptor antagonist, or a long-acting hormone receptor antagonist comprising a substitution of one or more amino acid residues in the amino acid sequence of the native long-acting hormone receptor antagonist or the mature long-acting hormone receptor antagonist.
[0002] This application discloses that it is the result of the research project "Development of Next-Generation Long-Acting Growth Hormone Receptor Antagonist" (Project Unique Number 9991007723, Project Number HN21C0535) conducted by the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, and the Ministry of Health and Welfare as part of the National New Drug Development Project.
[0003] Human growth hormone receptor (GHR) antagonists are compounds that bind to the human growth hormone receptor (GHR) and block its action. GH plays a crucial role in stimulating cell growth and division in the body, and in tissue growth and repair. Acromegaly is a rare disorder characterized by excessive secretion of growth hormone (GH), which leads to abnormal oversecretion of insulin-like growth factor-1 (IGF-1). It is most often caused by benign pituitary tumors. These GH-secreting pituitary tumors are the most common cause of acromegaly.
[0004] Treatment for acromegaly involves biochemically modulating insulin-like growth factor-1 levels, and drug therapy with growth hormone receptor antagonists can be a promising approach. The development of growth hormone receptor antagonists with minimal side effects is crucial.
[0005] The development of biopharmaceuticals for the treatment of acromegaly requires a recombinant protein-based therapeutic strategy. Proteins produced using recombinant technology exhibit consistent quality and activity, thereby enhancing the safety and efficacy of therapeutics and reducing variability during the production process. Furthermore, the target protein can be highly purified, resulting in highly pure pharmaceuticals, which reduces the risk of side effects and enhances therapeutic efficacy. Recombinant protein therapeutics enable the efficient production of large quantities of protein. This reduces the cost of therapeutics and allows access to a wider range of patients. To achieve high-throughput protein production, cell selection, media optimization, and improved culture processes can enhance the production efficiency and quality of recombinant proteins. Efforts are currently underway to optimize animal cell culture conditions to enhance the productivity and safety of therapeutically suitable proteins. This process not only increases productivity but also improves the purification process by suppressing the formation of deamidates, amino acid substitutions, and deletions, thereby maximizing the therapeutic efficacy of the resulting protein therapeutics.
[0006] Increased protein productivity is linked to animal cell metabolism, and the major metabolic pathways of animal cells utilize glucose and glutamine as their primary carbon and energy sources. When glucose is metabolized by animal cells, it undergoes glycolysis to produce pyruvate, similar to the process in bacteria. Furthermore, the pentose phosphate pathway produces pentose sugars, which are then used to synthesize nucleic acids, similar to the process in bacteria. Pyruvate produced during glycolysis is broken down into CO2 and H2O through the TCA cycle, or it can be converted into lactic acid or fatty acids. Among the carbon sources used in animal cell metabolism, glutamine, when metabolized, becomes glutamate, which then enters the TCA cycle to form the carbon skeleton for the synthesis of other amino acids. The main waste products of animal cell metabolism are lactate and ammonia, with the excretion of alanine also important. Lactate and ammonia are toxic to cells because they alter the pH within the cell and lysosomes. Therefore, effectively removing these substances is also a critical issue in high-density animal cell culture systems. Furthermore, the production of host cell proteins (HCPs) must be suppressed in animal cell culture, primarily to improve product purity, safety, and production efficiency. Target products (therapeutics, vaccines, etc.) produced during cell culture are often extracted along with host cell proteins, which can cause various problems. Host cell proteins are a contaminant for products requiring high purity. The presence of host cell proteins can negatively impact important quality attributes such as product activity, stability, and formulation. Therefore, minimizing the level of host cell proteins can improve product purity and quality. Host cell proteins are often recognized as foreign proteins and can trigger an immune response in the body.This may reduce the effectiveness of the drug or cause allergic reactions and side effects.
[0007] Therefore, reducing host cell protein levels can improve product safety. Food and drug regulatory agencies set strict standards for host cell protein levels in biological products. Compliance with these regulatory requirements is essential for product approval and commercialization, and reducing host cell protein levels is essential. Host cell proteins can complicate purification steps, such as chromatography, in the production process. Products with lower host cell protein levels can undergo simpler and more efficient purification processes, which can contribute to reduced production costs and increased yields. Various strategies are being used to suppress host cell proteins, including process improvements, optimization of cell culture conditions, and development of purification technologies.
[0008] Therefore, since the productivity and quality of a recombinant sustained-acting growth hormone receptor antagonist or a variant thereof are affected by culture conditions, research is required on a method for controlling and maintaining these conditions to increase the productivity of an industrially useful sustained-acting growth hormone receptor antagonist or a variant thereof.
[0009]
[0010] <Prior Art Literature>
[0011] <Non-patent literature>
[0012] Martins-Gomes C., et al. “The impact of hypothermia on cultured mammalian cells: a review.” Cryobiology. 2014 Oct; 69(2): 241-251.
[0013] Ramanathan A., et al. "Hypothermia: is it still a therapeutic strategy for severe traumatic brain injury?" Front Neurol. 2013 Oct 25; 4: 167.
[0014] Kiyono T., et al. "Low-temperature preservation of animal cells and microorganisms." Cell Preserv Technol. 2004; 2(1): 9-23.
[0015] Lindstrom J., et al. "Effects of hypothermia on mammalian cells in vitro: a review." In Vitro Cell Dev Biol Anim. 1993 Aug; 29A(8): 543-550.
[0016] Belzer FO., et al. "Organ preservation: II. Cold storage and perfusion of kidneys." Br J Surg. 1970 Jul; 57(7): 520-524.
[0017] Smith BJ., et al. "Cellular responses to hypothermia (20°C) in CHO-K1 cells." J Biotechnol. 2004 Oct 14; 112(1-2): 105-115.
[0018] Arshad A., et al. "The effect of hypothermia on the viability of cells in vitro." J Surg Res. 2001 May 1; 97(1): 34-39.
[0019] Elbashir SM., et al. "Host cell protein testing using mass spectrometry." Trends Biotechnol. 2018 Apr; 36(4): 352-360.
[0020] Huang L., et al. "The impact of host cell proteins on biologics characterization." Trends Biotechnol. 2018 Jun; 36(6): 629-643.
[0021] Liu H., et al. "Host-cell proteins in biologics development: Identification, quantification, and risk assessment." Biotechnol Bioeng. 2018 Sep; 115(9): 2175-2192.
[0022] Kelley B. "Industrialization of mAb production technology: the bioprocessing industry at a crossroads." MAbs. 2009 Jul-Aug; 1(4): 443-452.
[0023] Li M., et al. "Host cell protein dynamics in the supernatant of a mAb producing CHO cell line." Biotechnol Prog. 2018 Mar; 34(2): 393-402.
[0024] Harris RJ, Shire SJ, Winter C. Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies. Drug Dev Res. 2004 61:137-154.
[0025] H Tachibana 1, K Taniguchi, Y Ushio, K Teruya, K Osada, H Murakami. Changes of monosaccharide availability of human hybridoma lead to alteration of biological properties of human monoclonal antibody. Cytotechnology. 1994 16(3):151-7.
[0026] Veronica Restelli, Ming-Dong Wang, Norman Huzel, Martin Ethier, Helene Perreault, Michael Butler. The effect of dissolved oxygen on the production and the glycosylation profile of recombinant human erythropoietin produced from CHO cells. Biotechnol Bioeng. 2006 94:481-494.
[0027] Clark KJ, Chaplin FW, Harcum SW. Temperature effects on product quality-related enzymes in batch CHO cell cultures producing recombinant tPA. Biotechnol Prog. 2004 20:1888-1892.
[0028] The purpose of the present invention is to provide a method for culturing a host cell producing a recombinant long-acting growth hormone receptor antagonist or a variant thereof and a long-acting growth hormone receptor antagonist or a variant thereof produced by the method, and in particular, to provide a method for producing a long-acting growth hormone receptor antagonist or a variant thereof with improved productivity and quality.
[0029] However, the technical problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned can be clearly understood by those skilled in the art from the description of the specification of the present invention.
[0030] In the present invention, it was confirmed that when a host cell producing a recombinant sustained-release growth hormone receptor antagonist or a variant thereof is cultured under specific culture conditions, the productivity of the recombinant sustained-release growth hormone receptor antagonist or a variant thereof is significantly improved and the host cell protein expression is reduced.
[0031] Specifically, the present invention confirmed that the productivity of the long-acting growth hormone receptor antagonist or variant thereof desired in the present invention can be significantly increased by culturing for a certain period of time after changing the glucose concentration and / or culture temperature in the medium.
[0032] The present invention was completed by confirming that, in producing a long-acting growth hormone receptor antagonist or a variant thereof for industrial use by a genetic recombination method, animal cell culture conditions, particularly culture temperature, initial cell concentration, and glucose concentration in the culture medium, are very important for the productivity of the long-acting growth hormone receptor antagonist or a variant thereof.
[0033] By the method for producing a sustained-acting growth hormone receptor antagonist protein or a variant thereof according to the present invention, a sustained-acting growth hormone receptor antagonist protein or a variant thereof can be produced with high efficiency, thereby enabling mass production and supply of a sustained-acting growth hormone receptor antagonist protein or a variant thereof.
[0034] Figure 1 shows the results of analyzing the cell growth and cell viability, osmotic pressure and glucose concentration changes that produce a sustained growth hormone receptor antagonist according to cell culture temperature. Figure 1A shows cell growth, Figure 1B shows cell viability, Figure 1C shows culture medium osmotic pressure, and Figure 1D shows culture medium glucose concentration changes.
[0035] Figure 2 shows the results of HPLC analysis of the final expression level in response to the culture temperature of cells producing a sustained-release growth hormone receptor antagonist.
[0036] Figure 3 shows the results of analyzing cell growth, cell viability, and changes in cumulative cell concentration according to the initial cell concentration producing a sustained growth hormone receptor antagonist. Figure 3A shows cell growth, Figure 3B shows cell viability, and Figure 3C shows changes in cumulative cell concentration.
[0037] Figure 4 shows the results of HPLC analysis of the final expression level for the initial cell concentration of cells producing a sustained-acting growth hormone receptor antagonist.
[0038] Figures 5a to 5f show the results of analyzing cell growth, cell viability, pH, osmotic pressure, glucose concentration, and lactate concentration changes according to glucose concentration conditions for cells producing a sustained-acting growth hormone receptor antagonist. Figure 5a shows cell growth, Figure 5b shows cell viability, Figure 5c shows pH changes, Figure 5d shows osmotic pressure changes, Figure 5e shows glucose concentration changes, and Figure 5f shows lactate concentration changes.
[0039] Figure 6 shows the results of analyzing the protein expression level and host cell protein concentration according to glucose concentration conditions for cells producing a sustained-acting growth hormone receptor antagonist.
[0040] Specifically, the present invention
[0041] (1) A step of culturing a host cell expressing a sustained-acting growth hormone receptor antagonist or a variant thereof;
[0042] (2) Approximately 1.5×10 of the cultured host cells 6 A step of inoculating the medium with an initial cell concentration of 100 cells / mL or more and culturing at a culture temperature of 35°C to 38°C; and
[0043] (3) In the main culture of (2) above, the viable cell density is approximately 10x10 6 ~ 120x10 6 When the number of cells / mL is reached, the culture temperature is reduced to 28°C to 32°C, and then the culture temperature is maintained and the main culture is performed for 2 to 14 days.
[0044] The present invention relates to a method for producing a sustained-acting growth hormone receptor antagonist or a variant thereof, characterized in that the productivity of the sustained-acting growth hormone receptor antagonist or a variant thereof in the culture medium is increased and / or the expression of host cell proteins is reduced by maintaining the residual glucose concentration in the medium at 0.001 g / L to 5.0 g / L during the culture period in step (2) and / or step (3).
[0045] The above figures and those presented below are experimental values with a margin of error of, for example, 20%, preferably 15%, and even more preferably 10%. Since deviations may occur when establishing culture conditions depending on factors such as the equipment used for culture and the level of proficiency of the experimenter, the figures set in the present invention should be interpreted in a broader sense, taking into account the deviations, rather than in a limited sense.
[0046] Additionally, in this specification, the term "about" may be used before a specific numerical value. As used herein, the term "about" encompasses not only the exact number described after the term, but also a range that is approximately that number or near that number. Whether a number is close to or near the specific number described can be determined based on the context in which it is presented. For example, the term "about" may refer to a range of -15% to +15% of the numerical value described after the term. However, this is not a limitation.
[0047] The decrease in culture temperature from step (2) to step (3) is approximately 10x10 based on the viable cell density. 6 ~ 120x10 6 cells / mL, preferably about 13x10 6 ~ 100x10 6 cells / mL, more preferably about 15x10 6 ~ 80x10 6 It can be achieved when the viable cell density is approximately 10x10 cells / mL. 6 There is a problem that the target protein production decreases when the culture temperature is reduced below cells / mL, and the viable cell density is approximately 120x10 6 Reducing the culture temperature after cells / mL is exceeded may result in a rapid decline in cell viability.
[0048] In addition, the culture period in the above step (3) may be 2 to 15 days, preferably 3 to 14 days, and more preferably 4 to 13 days, but is not limited thereto.
[0049] For example, in the case of using a fed-batch culture method in the production of a sustained-acting growth hormone receptor antagonist or a variant thereof according to the present invention, the productivity of the sustained-acting growth hormone receptor antagonist or a variant thereof can be significantly increased by culturing at 33°C to 38°C until a certain cell concentration is reached in the seed culture using a perfusion culture method or a fed-batch culture method immediately before the main culture, then inoculating the seed culture into the main culture, reducing the temperature to below 33°C, preferably to 28°C to 32°C, and then culturing for 2 to 15 days, preferably 3 to 14 days, and more preferably 4 to 13 days.
[0050] The main culture cell inoculation concentration in step (2) above is approximately 1x10 5 cells / mL or more, preferably about 1.5x10 5 cells / mL or more, more preferably about 2x10 6 cells / mL or more, approximately 5x10 6 cells / mL or less, most preferably about 2.5x10 6 cells / mL or more, approximately 5x10 6 cells / mL or less, but is not limited thereto. The main culture cell inoculation concentration is approximately 1.5x10 5 There is a problem that the target protein production is low when the concentration is less than 5x10 cells / mL. In addition, if the main culture cell inoculation concentration is too high, for example, about 5x10 6 If cells / mL is exceeded, cell growth decline and / or cell viability may rapidly decrease.
[0051] In addition, the present invention relates to a method for producing a sustained-acting growth hormone receptor or a variant thereof, characterized in that the production of the sustained-acting growth hormone receptor or a variant thereof is performed through large-scale cell culture.
[0052] In addition, in the method for producing a sustained-acting growth hormone receptor antagonist or a variant thereof according to the present invention, the culture of the host cells in step (2) and / or step (3) may be performed by one or more methods selected from the group consisting of batch culture, repeated batch culture, fed-batch culture, repeated fed-batch culture, continuous culture, and perfusion culture, but is not limited thereto.
[0053] Batch culture is a culture method for proliferating cells without adding new medium or draining the culture medium during culture. Continuous culture is a culture method in which medium is continuously added and also drained during culture. Continuous culture also includes perfusion culture. Fed-batch culture is a culture method that falls between batch culture and continuous culture, and is also called semi-batch culture. It is a culture method in which medium is continuously or sequentially added during culture, but continuous culture fluid is drained like continuous culture, but there is no cell outflow. In the present invention, either culture method may be used, but preferably, fed-batch culture or continuous culture is used, and more preferably, fed-batch culture is used.
[0054] In the production of a sustained-acting growth hormone receptor antagonist or a variant thereof according to the present invention, it is most preferable to culture using a combined fed-batch culture method and a perfusion culture method, thereby maximizing the productivity of the sustained-acting growth hormone receptor antagonist or a variant thereof, and also significantly increasing the productivity of the produced sustained-acting growth hormone receptor antagonist or a variant thereof.
[0055] In the present invention, the culture can be performed while maintaining the residual glucose concentration in the medium at 0.001 g / L to 5.0 g / L, preferably 0.01 to 4.0 g / L, and more preferably 0.1 to 3.5 g / L, but is not limited thereto.
[0056] In the present invention, the meaning of “cultivating while maintaining the residual glucose concentration in the medium at 0.001 g / L to 5.0 g / L, preferably 0.01 to 4.0 g / L, and more preferably 0.1 to 3.5 g / L” means that during the culturing period, the residual glucose concentration in the medium is measured every 1 to 36 hours, preferably every 3 to 30 hours, and more preferably every 6 to 24 hours, or in real time, and if the residual glucose concentration in the medium is lower than the standard concentration set at 0.001 g / L to 5.0 g / L, preferably 0.01 to 4.0 g / L, and more preferably 0.1 to 3.5 g / L, a glucose stock solution is added to the medium to culture so as to bring the standard concentration to the level.
[0057] In the present invention, the standard concentration of residual glucose in the medium can be set within the range of 0.001 g / L to 5.0 g / L, preferably 0.01 to 4.0 g / L, and more preferably 0.1 to 3.5 g / L, and it is obvious to those skilled in the art that the standard concentration can be appropriately changed during the culturing period. For example, on the first 1 to 2 days, the standard concentration of residual glucose in the medium can be cultured at 2 g / L, and on the 3rd to 5th days, the standard concentration can be lowered to 1.5 g / L and cultured. Thereafter, the standard concentration can be set again to 2 g / L, or the standard concentration can be set to a lower concentration than 1.5 g / L, that is, 1.0 g / L, and cultured.
[0058] In addition, the present invention provides a method for culturing host cells in step (2) and / or step (3).
[0059] (i) Conditions for adding glucose to the medium at about 5 g / L or less when the residual glucose concentration in the medium is below the standard value;
[0060] (ii) a condition of adding to the medium one or more substances selected from the group consisting of glutamine and insulin; and
[0061] (iii) a method for producing a sustained-release growth hormone receptor or a variant thereof, characterized in that the method is performed under one or more conditions selected from the group consisting of: a condition in which lactate is not added to a medium;
[0062] More specifically, in the method for producing a sustained-acting growth hormone receptor antagonist or a variant thereof according to the present invention, the culturing of the host cells in step (2) and / or step (3) may be characterized by, but is not limited to, adding about 5 g / L of glucose or less to the medium and / or reducing lactate in the medium and / or culturing without adding lactate to the medium, and / or culturing by adding glutamine and / or insulin. Animal cells use glucose to obtain energy. There are two main pathways that occur in this process. The aerobic pathway is where glucose is completely oxidized to effectively generate energy. This process provides the energy required for cellular activities such as polymer formation, cell division, and DNA replication. The other is the anaerobic pathway, in which glucose is partially oxidized, and lactate is generated in the process. Excessively generated lactate is discharged outside the cells, lowering the pH of the culture medium, inhibiting cell growth and division, and in the worst case, causing cell death. Therefore, if too much glucose is added, excessive lactate is produced during the cell energy production process, which is detrimental to the cells. Therefore, the amount of glucose added must be appropriately controlled to prevent this problem in cell culture. Glutamine and / or insulin are required for cellular energy production, protein synthesis, and cell division, respectively, and are essential for promoting cell growth and survival in cell culture. Glutamine is an essential amino acid for cells. It is essential for cellular energy production and plays a crucial role in protein synthesis, cell division, and antibody production. It also helps cells recover from stress conditions and prevents cell death. Insulin promotes cellular glucose uptake and promotes cellular energy metabolism.It also promotes cell growth and division, which helps in cell division by promoting DNA synthesis within the cell and promoting the G1 / S transition of the cell cycle.
[0063] In addition, as host cells used for expression of the sustained growth hormone receptor antagonist protein in the present invention, animal cells, yeast, actinomycetes, and insect cells can be used, but are not limited thereto.
[0064] Animal cells are preferably mammalian cells. More preferably, animal culture cells commonly used for cell culture are used, such as CHO cells, HEK cells, COS cells, 3T3 cells, myeloma cells, BHK cells, HeLa cells, and Vero cells. CHO cells are particularly preferred when mass expression is desired. In addition, in order to produce a desired protein, dhfr, a CHO cell lacking the DHFR (Dihydrofolate reductase) gene, is particularly preferred. - It is preferable that the cell be suitable for introducing a desired gene, such as a CHO cell (Proc. Natl. Acad. Sci. USA (1980) 77, 4216-4220) or a CHO K-1 cell (Proc. Natl. Acad. Sci. USA (1968) 60, 1275). As the CHO cell, the DG44 strain, the DXB-11 strain, the K-1 strain or the CHO-S strain is particularly preferable, and the introduction of the vector into the host cell can be carried out by a method such as the calcium phosphate method, the DEAE dextran method, the electroporation method or the lipofection method.
[0065] Examples of yeasts include, but are not limited to, Sacchromyces sp., Hansenula sp., Kluyveromyces, and Pichia sp., and examples of actinomycetes include, but are not limited to, Streptomyces.
[0066] As described above, the long-acting growth hormone receptor antagonist or variant thereof produced by the production method according to the present invention can have an expression level increased by at least 10% compared to that produced by conventional methods. This increase in expression level is dependent on the cell culture conditions of the long-acting growth hormone receptor antagonist or variant thereof produced by the production method according to the present invention.
[0067] In the present invention, the medium used to culture cells and express proteins is preferably a serum-free medium, but is not limited thereto, and more preferably, DMEM / F12 medium (a mixed medium of DMEM and F12) can be used as the basic medium. In addition, commercially available serum-free medium, for example, HycellCHO medium, ActiPro medium (Hyclone, USA), CD OptiCHO TM Badge, CHO-S-SFM II Badge, CD CHO Badge, or Efficient-Pro TM Badge (Gibco, USA), IS CHO-V TM The basic medium may include, but is not limited to, EX-CELL® Advanced CHO Fed-Batch Medium (Sigma-Aldrich, USA), Irvine Scientific, USA, etc.
[0068] In the present invention, the feed medium used to culture cells and express glycoproteins is a serum-free medium, for example, Cell Boost TM 1. Cell BoostTM 2. Cell Boost TM 3. Cell Boost TM 4. Cell Boost TM 5. Cell Boost TM 6. Cell Boost TM 7a / 7b (Hyclone, USA), CD CHO EfficientFeed TM A AGT TM , CD CHO EfficientFeed TM B AGT TM , CD CHO EfficientFeed TM C AGT TM , CD CHO EfficientFeed TM A plus AGT TM , CD CHO EfficientFeed TM B plus AGT TM , CD CHO EfficientFeed TM C plus AGT TM (Gibco, USA), BalanCD ® CHO Feed 4 (Irvine Scientific, USA), EX-CELL ® Feed media may include, but are not limited to, Advanced CHO Feed (Sigma-Aldrich, USA), CHO-U Feed Mix U1B7 / CHO-U Feed Mix U2B13 (Kerry, USA).
[0069] The terms "feed medium" and "concentrated nutrient medium" used in the present invention refer to a medium composed of specific nutrients or multiple nutrients such as amino acids, vitamins, salts, trace elements, lipids, and glucose, which may be a concentrated product of a basic medium, and the components and concentrations of the feed medium may be manufactured and used in various ways depending on the cells to be cultured. In addition, commercially available feed media, for example, Cell Boost Series supplement medium (Hyclone, USA), EfficientFeed supplement medium, GlycanTune feed medium (Gibco, USA), BalanCD CHO feed medium (Irvine Scientific, USA), Cellvento® CHO Cell Culture feed medium (Merck, USA), EX-CELL® Advanced CHO feed medium (Sigma-Aldrich, USA), etc., may be used as feed media, but are not limited thereto.
[0070] The plant-derived hydrolysate used in the present invention refers to a product extracted from garden pea, cottonseed, wheat gluten, soybeans, etc., and does not contain animal-derived components, and is a supplement rich in amino acids, peptides, vitamins, carbohydrates, nucleotides, minerals, and other components. This can also be produced and used by varying the composition and concentration of the plant-derived hydrolysate depending on the cultured cells. In addition, commercially available plant-derived hydrolysates, such as Hy-Pea™7404, UltraPep™ Cotten, Hy-Pep™ 7504, Hy-Pep™ 4601N (Kerry, USA), Cotton 100, Cotton 200, Phytone™Soy 100 (Gibco, USA), etc., can be used as supplements, but are not limited thereto.
[0071] The medium additives used in the present invention serve to promote cell division and cell survival, promote intracellular ATP synthesis, and supply phosphorylated intermediates necessary for nucleic acid synthesis. In addition, they serve to promote protein synthesis or reduce oxidative stress and play an important role in intracellular metabolism. These can also be selected and used depending on the cells being cultured. Examples include insulin, IGF (Insulin-like Growth Factor) (Gibco, USA), Long-R3 IGF-1 (Repligen, USA), transferrin (Sigma-Aldrich, USA), and CELLiST. TM Supplement Cys1, CELLiST TM Supplement Cys2 (Ajinomoto Genexine, Korea) can be used as a supplement, but is not limited to these.
[0072] Most animal cell cultures primarily use media containing serum. However, serum-containing media are complex compounds with unclear chemical compositions, making it difficult to design media suitable for protein production. Serum use not only poses cost and reproducibility challenges, but can also negatively impact separation and purification. Therefore, serum-free or low-serum media are primarily used. Because the concentration of glucose, the carbon source, is significantly low in serum-free media, cells are cultured with glucose, the primary carbon source, added to the medium to maintain cell growth and produce high concentrations of the target protein. Glutamine can also be added during culture. In particular, in protein pharmaceutical production, glucose and glutamine must be maintained above a certain concentration without being depleted to increase sialylation levels, which increases the half-life of protein pharmaceuticals in the body. The glucose and glutamine concentrations measured in the culture medium represent the residual concentrations of each substance used by the cells.
[0073] In addition, the present invention relates to a method for producing a long-acting growth hormone receptor antagonist or a variant thereof, which further includes a process for recovering the long-acting growth hormone receptor antagonist or a variant thereof from a culture medium in which cells producing the long-acting growth hormone receptor antagonist or a variant thereof are cultured.
[0074] Furthermore, the present invention relates to a long-acting growth hormone receptor antagonist or a variant thereof, characterized by being produced by the above-described production method. The long-acting growth hormone receptor antagonist or variant thereof produced by the above-described method is characterized by a reduced host cell protein content and thus an increased purity.
[0075] In addition, the present invention relates to a pharmaceutical composition comprising a sustained-release growth hormone receptor antagonist or a variant thereof having a reduced host cell protein content and increased purity, prepared by the above method.
[0076]
[0077] All technical and scientific terms used in this specification have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs, unless otherwise specified.
[0078]
[0079] Hereinafter, the composition of the present invention will be described in more detail through examples. However, these examples are intended to illustrate the present invention, and the scope of the present invention is not limited by these examples.
[0080]
[0081] Example 1. Culture temperature conditions
[0082] In a 125 mL flask, 2x10 cells overexpressing a long-acting growth hormone receptor antagonist were cultured in Efficient-Pro™AGT™ medium (Gibco, USA) supplemented with 8 mM L-glutamine (Sigma-Aldrich, USA) and 2 g / L Phytone (Gibco, USA). 6 cells / mL and cultured in a 35°C CO2 incubator with shaking. On the second day of culture, EX-CELL®Advanced™ CHO feed medium (Sigma-Aldrich, USA), a concentrated nutrient medium, was used as a feed medium and fed-batch culture was performed. After initial culture at 35°C and 35°C, when the viable cell concentration reached the change range, the culture temperature was changed to 30°C and fed-batch culture was performed respectively. EX-CELL®Advanced™ CHO feed medium (Sigma-Aldrich, USA) was supplied daily at 0.8% of the starting culture volume in a 125 mL flask. Culture was carried out until the cell viability became 40% or less, and the culture was terminated on the 13th or 14th day. Various conditions of the cells were measured daily from the culture medium, including the number of viable cells, cell viability, culture medium osmotic pressure, and glucose concentration levels. After the culture was terminated, the culture supernatant was secured by centrifugation at 4℃10,000 rpm for 60 minutes. The expression level of the sample cultured under the above conditions was confirmed by RP-HPLC analysis. It was confirmed that the cells grown at the reduced culture temperature had a low integral viable cell density, but the expression level increased by about 10% (Fig. 1, Fig. 2).
[0083]
[0084] Example 2. Initial cell concentration conditions
[0085] In a 125 mL flask, 1.6 x 10 cells overexpressing a long-acting growth hormone receptor antagonist were cultured in Efficient-Pro™AGT™ medium (Gibco, USA) supplemented with 8 mM L-glutamine (Sigma-Aldrich, USA) and 2 g / L Phytone (Gibco, USA). 6 cells / mL, 3.0x10 6 cells / mL, 4.4x10 6 Each cell was inoculated to be 100 cells / mL and cultured with shaking in a 35°C CO2 incubator. On the second day of culture, EX-CELL®Advanced™ CHO feed medium (Sigma-Aldrich, USA), a concentrated nutrient medium, was used as a feed medium and cultured using a fed-batch method. After initial culture under 35°C conditions, when the viable cell concentration reached the change range, the temperature was lowered to 30°C and fed-batch culture was performed. EX-CELL®Advanced™ CHO feed medium (Sigma-Aldrich, USA), a feed medium, was supplied daily at 1.25% of the starting culture volume in a 125 mL flask. On the 14th day of culture, the culture was terminated, and the culture medium was collected daily to measure the number of viable cells, cell viability, and cumulative cell density (integral viable cell density). After the culture was terminated, the culture supernatant was secured by centrifugation at 4℃, 10,000 rpm for 60 minutes. The expression amount of the samples cultured under the above conditions was confirmed by RP-HPLC analysis. It was confirmed that the expression amount increased by 45% under conditions where the initial cell concentration increased (Fig. 3, Fig. 4).
[0086]
[0087] Example 3. Control of glucose concentration in culture medium
[0088] In a 125 mL flask, 3.0 x 10 cells overexpressing a long-acting growth hormone receptor antagonist were cultured in Efficient-Pro™AGT™ medium (Gibco, USA) supplemented with 8 mM L-glutamine (Sigma-Aldrich, USA), 2 g / L Phytone (Gibco, USA), 10 g / L glucose (Sigma-Aldrich, USA), and 10 mg / L insulin (Gibco, USA). 6 Each cell was inoculated to be 100 cells / mL and cultured in a 35°C CO2 incubator with shaking. On the second day of culture, fed-batch culture was performed using EX-CELL®Advanced™ CHO feed medium (Sigma-Aldrich, USA) containing cys1 supplement (Ajinomoto Genexine, Korea) as a feed medium in a concentrated nutrient medium. After initial culture at 35°C, when the viable cell concentration reached the change range, the temperature was lowered to 30°C and fed-batch culture was performed. EX-CELL®Advanced™ CHO feed medium (Sigma-Aldrich, USA) was supplied daily at 2.0% (v / v) of the starting culture volume in a 125 mL flask.
[0089] The glucose concentration in the culture medium was measured daily, and the glucose concentration in the medium was adjusted from the point when the glucose concentration measured was below the reference concentration due to consumption by cell growth. When the measured glucose concentration was below the reference concentration, 200 g / L glucose stock solution was added within 3 hours in an amount reaching the reference concentration, and when the measured glucose concentration was above the reference concentration, no addition was made, thereby maintaining each glucose concentration condition. Generally, in animal cell culture, changes in glucose content have a minimal effect on cell growth within 3 hours.
[0090] In this case, the condition of maintaining 2 g / L as the reference concentration is called the 1 g / L (±1 g / L) concentration condition, the condition of maintaining 4 g / L as the reference concentration is called the 3 g / L (±1 g / L) concentration condition, the condition of maintaining 6 g / L as the reference concentration is called the 5 g / L (±1 g / L) concentration condition, and the condition of maintaining 8 g / L as the reference concentration is called the 7 g / L (±1 g / L) concentration condition. For example, the glucose concentration maintenance condition of 1 g / L (±1 g / L) means that the lower limit of the glucose concentration control range is set to 0 g / L, and the upper limit of the glucose concentration control range is set to 2 g / L. In actual culture, when the glucose concentration measured in the culture medium reaches the lower limit of 0 g / L, an additional 200 g / L of glucose stock solution is added to achieve a maximum glucose concentration of 2 g / L, and when the glucose concentration in the culture medium reaches the upper limit of 2 g / L, the 200 g / L glucose stock solution is not added. Therefore, among the two concentration conditions of 1 g / L (±1 g / L) and 3 g / L (±1 g / L), the concentration condition of 2 g / L refers to the upper limit condition at the 1 g / L (±1 g / L) concentration and refers to the lower limit condition at the 3 g / L (±1 g / L) concentration. Since these are conditions in which completely different actions occur, they cannot be said to be overlapping conditions.
[0091] On the 14th day of culture, the culture was terminated, and the number of viable cells, cell viability, culture medium pH, culture medium osmotic pressure, culture medium glucose concentration, and culture medium lactate concentration were measured daily. After the culture was terminated, the culture medium supernatant was secured by centrifugation at 4℃, 10,000 rpm for 60 minutes. The expression amount of the samples cultured under the above conditions was confirmed by RP-HPLC analysis. It was confirmed that the expression amount decreased as the glucose concentration in the culture medium increased, whereas the host cell protein content increased (Figs. 5a to 5f, Fig. 6).
Claims
1. (1) A step of culturing a host cell expressing a sustained-acting growth hormone receptor antagonist or a variant thereof; (2) Approximately 1.5×10 of the cultured host cells 6 A step of inoculating the medium with an initial cell concentration of 100 cells / mL or more and culturing at a culture temperature of 35°C to 38°C; and (3) In the main culture of (2) above, the viable cell density is approximately 10x10 6 ~ 120x10 6 When the number of cells / mL is reached, the culture temperature is reduced to 28°C to 32°C, and then the culture temperature is maintained and the main culture is performed for 2 to 14 days. A method for producing a sustained-acting growth hormone receptor antagonist or a variant thereof, characterized in that the productivity of a sustained-acting growth hormone receptor antagonist or a variant thereof in a culture medium is increased by maintaining the residual glucose concentration in the medium at 0.001 g / L to 5.0 g / L during the culture period in step (1) and / or step (2) and the host cell protein expression is reduced.
2. In paragraph 1, In step (2) above, the initial cell concentration is approximately 2×10 6 cells / mL or more, approximately 5×10 6 A method for producing a sustained-release growth hormone receptor or a variant thereof, characterized in that the number of cells / mL is less than or equal to 100 cells.
3. A method for producing a sustained-acting growth hormone receptor or a mutant thereof, characterized in that the production of the sustained-acting growth hormone receptor or a mutant thereof in paragraph 1 is performed by large-scale cell culture.
4. A method for producing a sustained growth hormone receptor or a variant thereof, characterized in that the host cell main culture of step (2) and / or step (3) in paragraph 1 is performed by at least one method selected from the group consisting of batch culture, repeated batch culture, fed-batch culture, repeated fed-batch culture, continuous culture, and perfusion culture.
5. In the first paragraph, the host cell main culture of step (2) and / or step (3) (i) Conditions for adding glucose to the medium at 5 g / L or less; (ii) a condition of adding to the medium one or more substances selected from the group consisting of glutamine and insulin; and (iii) Conditions in which lactate is not added to the medium; A method for producing a sustained-release growth hormone receptor or a variant thereof, characterized in that the method is performed under one or more conditions selected from the group consisting of:
6. A method for producing a sustained growth hormone receptor or a variant thereof, characterized in that the host cell in paragraph 1 is an animal cell, yeast, actinomycetes, or insect cell.
7. A method for producing a long-acting growth hormone receptor antagonist or a variant thereof, further comprising a step of recovering the long-acting growth hormone receptor antagonist or a variant thereof from a culture medium in which cells producing the long-acting growth hormone receptor antagonist or a variant thereof are cultured, in accordance with claim 1.
8. A long-acting growth hormone receptor antagonist or a variant thereof, characterized by being produced by the method of any one of claims 1 to 7.
9. A pharmaceutical composition comprising a long-acting growth hormone receptor antagonist or a variant thereof prepared by the method of paragraph 1.
Citation Information
Patent Citations
Station and method for filling one or more tank(s)
KR1020210094471A
Magnetic wheel and platform for non-destructive inspection including the same
KR1020230123044A
Film composition for Anti-corrosion having self-adhesion by blooming and manufacturing method thereof
KR102053156B1
Automated molding device for vehicle carpet
KR102404568B1
Combination therapy
US20160143999A1
